Alto Neuroscience, Inc.
Alto Neuroscience, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||
Assets Current | ||||||||||||||
Cash And Cash Equivalents At Carrying Value | 264 | 176 | 138 | 148 | 161 | 168 | 182 | 193 | 206 | |||||
Other Receivables Net Current | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Prepaid Expense And Other Assets Current | 5 | 1 | 2 | 2 | 3 | 1 | 2 | 2 | 2 | |||||
Assets Current | 269 | 178 | 139 | 150 | 164 | 169 | 184 | 195 | 208 | |||||
Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | |||||
Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | 2 | |||||
Operating Lease Right Of Use Asset | 4 | 4 | 4 | 5 | 5 | 5 | 5 | - | - | |||||
Other Assets | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||||
Assets | 276 | 185 | 147 | 158 | 172 | 178 | 192 | 197 | 210 | |||||
Liabilities And Stockhold… | ||||||||||||||
Liabilities | ||||||||||||||
Liabilities Current | ||||||||||||||
Accounts Payable Current | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | |||||
Accrued Liabilities Current | 8 | 9 | 7 | 6 | 6 | 8 | 8 | 6 | 4 | |||||
Long Term Debt Current | 2 | 1 | - | - | - | 0 | 4 | 2 | 1 | |||||
Liabilities Current | 13 | 11 | 9 | 8 | 7 | 10 | 14 | 10 | 8 | |||||
Long Term Debt Noncurrent | 14 | 16 | 20 | 20 | 20 | 10 | 7 | 8 | 9 | |||||
Warrants And Rights Outstanding | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Convertible Debt | 2 | 2 | 2 | 2 | 1 | 1 | 1 | - | - | |||||
Operating Lease Liability Noncurrent | 4 | 4 | 4 | 4 | 4 | 5 | 5 | - | - | |||||
Liabilities | 33 | 34 | 35 | 34 | 33 | 26 | 27 | 18 | 17 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | 0 | - | - | - | 0 | 0 | 0 | 0 | |||||
Stockholders Equity Inclu… | ||||||||||||||
Stockholders Equity Note | ||||||||||||||
Common Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 471 | 353 | 297 | 295 | 293 | 290 | 288 | 286 | 284 | |||||
Retained Earnings Accumulated Deficit | -228 | -202 | -185 | -171 | -154 | -138 | -123 | -106 | -90 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | |||||
Stockholders Equity | 243 | 151 | 112 | 123 | 139 | 151 | 165 | 180 | 193 | |||||
Liabilities And Stockholders Equity | 276 | 185 | 147 | 158 | 172 | 178 | 192 | 197 | 210 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | - | - | |||||
Common Stock Shares Issued | 35 | 32 | 27 | 27 | 27 | 27 | 27 | - | - | |||||
Shares Outstanding | 35 | 32 | 27 | 27 | 27 | 27 | 27 | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.09% | 8.45% | 18.47% | - | - | - | - | - | - | - | - | - |
| 2025 | 16.82% | 6.82% | 38.64% | 17.25% | 120.13% | 353.35% | -5.42% | 16.83% | 9.01% | -6.22% | -0.12% | -24.83% |
| 2024 | -16.60% | -17.58% | -35.66% | 46.66% | 16.37% | -55.68% | -13.11% | 2.44% | -4.67% | -20.82% | -17.47% | -4.46% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Alto Neuroscience, Inc. (ANRO) — SEC Financial Statements & Analysis
Alto Neuroscience, Inc. (ANRO) is a pharmaceutical preparations company, incorporated in DE. Alto Neuroscience, Inc. trades on NYSE as: ANRO. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Alto Neuroscience, Inc. reported a Debt-to-Equity ratio of 0.14x, a Price-to-Book (P/B) ratio of 3.04 (TTM), at a market cap of $739.43M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.14x
- P/B TTM
- 3.04
- Market Cap
- $739.43M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alto Neuroscience, Inc. in?
Alto Neuroscience, Inc. (ANRO) operates in the Pharmaceutical Preparations industry.
What is ANRO's market cap?
Alto Neuroscience, Inc. (ANRO) has a market capitalization of $739.43M as of 2026-03-31.
What exchange does ANRO trade on?
Alto Neuroscience, Inc. (ANRO) trades on the NYSE.
Where is Alto Neuroscience, Inc. incorporated?
Alto Neuroscience, Inc. is incorporated in DE.